Chapter 52: Smoking Cessation – Pharmacologic Strategies

Smoking Cessation – Pharmacologic Strategies pharmacotherapeutics chapter thoroughly addresses nicotine addiction and tobacco use disorder as a chronic medical condition, emphasizing that tobacco use remains the foremost preventable cause of morbidity and mortality in the United States, driving high rates of lung cancer, COPD, and cardiovascular diseases. The physiological basis of addiction is explored through the mechanism of nicotine, the addictive substance found in various products like cigarettes, smokeless tobacco, and ENDS, which acts as a cholinergic receptor agonist in the body. Clinical assessment relies on tools such as the APA criteria for tobacco use disorder and the Fagerstrom Test for Nicotine Dependence, which uses the time to first cigarette (TTFC) as a key indicator of physical dependence. Effective cessation treatment requires consistent intervention, combining behavioral counseling with pharmacologic agents. Behavioral interventions should follow guidelines like the Five A’s (Ask, Advise, Assess, Assist, Arrange) and utilize motivational interviewing techniques like the Five R’s, while assessing the patient's readiness to quit using the Transtheoretical Stages of Change model (Precontemplation through Maintenance). First-line pharmacotherapies approved by the FDA include Nicotine Replacement Therapy (NRT), available in multiple forms (patches, gum, lozenge, nasal spray, inhaler), which aims to prevent withdrawal symptoms by providing steady, low levels of nicotine. The non-nicotine options are bupropion SR (Zyban), which has dual use for depression and may help delay weight gain, and varenicline (Chantix), a partial agonist that reduces the rewarding sensation of smoking. Combination therapy, typically involving a long-acting nicotine patch plus a fast-acting NRT for acute cravings, has shown superior success rates over monotherapy. Special considerations are necessary for pregnant women, adolescents, and patients with certain comorbidities like cardiovascular disease or a history of neuropsychiatric issues, especially when prescribing varenicline.